Recent Analysts’ Ratings Changes for Insmed (INSM)

A number of research firms have changed their ratings and price targets for Insmed (NASDAQ: INSM):

• 8/21/2025 – Insmed had its price target raised by analysts at Morgan Stanley from $126.00 to $144.00. They now have an “equal weight” rating on the stock.
• 8/20/2025 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $111.00 to $135.00. They now have an “overweight” rating on the stock.
• 8/20/2025 – Insmed is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 8/14/2025 – Insmed had its price target raised by analysts at Truist Financial Corporation from $126.00 to $139.00. They now have a “buy” rating on the stock.
• 8/14/2025 – Insmed had its price target raised by analysts at Stifel Nicolaus from $121.00 to $145.00. They now have a “buy” rating on the stock.
• 8/13/2025 – Insmed had its price target raised by analysts at Mizuho from $130.00 to $165.00. They now have an “outperform” rating on the stock.
• 8/13/2025 – Insmed had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $126.00 price target on the stock.
• 8/13/2025 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $114.00 to $142.00. They now have a “buy” rating on the stock.
• 8/13/2025 – Insmed had its price target raised by analysts at Jefferies Financial Group Inc. from $129.00 to $148.00. They now have a “buy” rating on the stock.
• 8/12/2025 – Insmed had its price target raised by analysts at Wells Fargo & Company from $130.00 to $140.00. They now have an “overweight” rating on the stock.
• 8/8/2025 – Insmed had its price target raised by analysts at UBS Group AG from $124.00 to $133.00. They now have a “buy” rating on the stock.
• 8/8/2025 – Insmed had its price target raised by analysts at Royal Bank Of Canada from $108.00 to $120.00. They now have an “outperform” rating on the stock.
• 7/22/2025 – Insmed had its price target raised by analysts at Wells Fargo & Company from $119.00 to $130.00. They now have an “overweight” rating on the stock.
• 7/17/2025 – Insmed had its price target raised by analysts at Morgan Stanley from $102.00 to $108.00. They now have an “overweight” rating on the stock.
• 7/8/2025 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $111.00. They now have an “overweight” rating on the stock.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the completion of the transaction, the chief operating officer directly owned 105,637 shares of the company’s stock, valued at approximately $13,477,168.46. This represents a 19.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the transaction, the chief financial officer directly owned 73,505 shares of the company’s stock, valued at $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 532,864 shares of company stock valued at $52,657,556. 3.00% of the stock is owned by insiders.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.